Health & Fitness
Thu, July 19, 2012Wed, July 18, 2012Tue, July 17, 2012Mon, July 16, 2012Fri, July 13, 2012Thu, July 12, 2012Wed, July 11, 2012Tue, July 10, 2012Mon, July 9, 2012Fri, July 6, 2012Thu, July 5, 2012Wed, July 4, 2012Tue, July 3, 2012Mon, July 2, 2012Sun, July 1, 2012Fri, June 29, 2012Thu, June 28, 2012Wed, June 27, 2012Tue, June 26, 2012Mon, June 25, 2012Cempra, Inc. to Present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference
//health-fitness.news-articles.net/content/2012/ .. tives-partnering-and-deal-making-conference.html
Published in Health and Fitness on Friday, July 6th 2012 at 13:11 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
Cempra, Inc. to Present at the Global Technology Community 9th Anti-Infectives... -- CHAPEL HILL, N.C., July 6, 2012 /PRNewswire/ --
Cempra, Inc. to Present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference
CHAPEL HILL, N.C., July 6, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: [ CEMP ]) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the [ Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference ] on July 9 to 10 at the San Francisco Airport Marriott Waterfront Hotel in San Francisco. Dr. Fernandes will participate in a panel discussion entitled Current Trends and Future Anti-Infectives Development to be held at 10:30 a.m. PDT on July 9. She will also give a presentation at noon PDT on July 10 that will provide an overview of solithromycin, Cempra's fluoroketolide in clinical development for the treatment of community-acquired bacterial pneumonia.
About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at [ www.cempra.com ].
Investor Contacts: Robert E. Flamm, Ph.D. Russo Partners, LLC (212) 845-4226 [ Robert.flamm@russopartnersllc.com ]
Andreas Marathovouniotis Russo Partners, LLC (212) 845-4235 [ Andreas.marathis@russopartnersllc.com ]
Media Contact: Elliot Fox Russo Partners, LLC (212) 845-4253 [ Elliot.fox@russopartnersllc.com ]
SOURCE Cempra, Inc.
[ Back to top ]
RELATED LINKS
[ http://www.cempra.com ]
